Table 2.

Tracking ADSCs testing from processing to delivery to the point of care

Processing conditions before administration	Location	Performed actions before delivery	Proposed actions before delivery	Actions on the point of care
Separated ADSCs (autologous use)	Patient bedside Cell therapy units under GLP and GCP	Viability, cell dose Functional assay (CFU-F) CD73, CD90, CD105, CD34, CD45, CD14, HLA-DR Microbial, endotoxine, mycoplasma testing	CD271, CD274, CD276, CD163, CD63 expression Cytometry and q-RT-PCR	Viability Sterility apoptotic activity
Cryopreserved and thawed (autologous and allogenic use)	Stem cell facility under GMP	Viability, cell dose Functional assay (CFU-F) CD73, CD90, CD105, CD34, CD45, CD14, HLA-DR Microbial, endotoxine, mycoplasma testing	CD271, CD274, CD276, CD163, CD63 expression Apoptotic activity IL-6, TNF-α and IFN expression level (q-RT-PCR)	Viability Sterility Apoptotic activity
Cryopreserved, thawed and expanded (autologous and allogenic use)	Stem cell facility under GMP	Viability, cell dose Functional assay (CFU-F) CD73, CD90, CD105, CD34, CD45, CD14, HLA-DR Microbial, endotoxine, mycoplasma testing	CD271, 274, CD276, CD163, CD63 expression Apoptotic activity Karyotype Migration’s genes IL-6, TNF-α, and IFN expression level (q-RT-PCR)	Viability Sterility Apoptotic activity

ADSCs can be used after separation, cryopreservation, or cryopreservation and expansion processes. During these procedures, and regarding the medical devices used to separate SVF and ADSCs and to the stem cell facilities, variabilities in cell efficiency and clinical outcomes are observed. Continuous and standardized guidelines are proposed and reinforced through a flow chart during cell processing before delivery and in the point of care

GLP good laboratory practices, GCP good cell practices, GMP good manufacturing practices